CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. (Q52589075)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29654297%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

title

CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29654297%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29654297%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Mario Schiffer

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29654297%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

author name string

Tobias B Huber

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29654297%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Berend Isermann

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29654297%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

language of work or name

English

0 references

publication date

1 June 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29654297%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Nephrology

23 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29654297%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29654297%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

page(s)

361-377

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29654297%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29654297%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/s41581-018-0001-y

23 March 2020

exact match

0 references

cites work

Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

1 reference

7 January 2021

Long-term effects of intensive glucose lowering on cardiovascular outcomes

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Complications of Diabetes Diagnosed in Children and Adolescents-Reply

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Pathologic classification of diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Assessment of Global Kidney Health Care Status

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Diabetic nephropathy: Is it time yet for routine kidney biopsy?

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

The modern spectrum of renal biopsy findings in patients with diabetes

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Differences in acute kidney injury ascertainment for clinical and preclinical studies.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Diabetic nephropathy research in China: Data analysis and review from the National Natural Science Foundation of China

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Diabetes Control and the Risks of ESRD and Mortality in Patients With CKD

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Cardiac and Renovascular Complications in Type 2 Diabetes--Is There Hope?

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Changes in diabetes-related complications in the United States, 1990-2010

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Role of blood pressure and the renin-angiotensin system in development of diabetic nephropathy (DN) in eNOS-/- db/db mice.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Liraglutide and Renal Outcomes in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Nephron Protection in Diabetic Kidney Disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Anti-TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Albuminuria and estimated glomerular filtration rate as predictors of diabetic end-stage renal disease and death

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

1 reference

7 January 2021

Predictors for the development of microalbuminuria and interaction with renal function.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Clinical implications of pathologic diagnosis and classification for diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Effect of blood glucose control on increased glomerular filtration rate and kidney size in insulin-dependent diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Improved glycemic control and risk of ESRD in patients with type 1 diabetes and proteinuria

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Is diabetic nephropathy reversible?

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Genetics of diabetic nephropathy: a long road of discovery.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

A more tubulocentric view of diabetic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Vascular endothelium in diabetes

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Endothelial dysfunction plays a key role in increasing cardiovascular risk in type 2 diabetes: the Hoorn study

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Glomerular endothelial cell injury and cross talk in diabetic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Selective decreased de novo synthesis of glomerular proteoglycans under the influence of reactive oxygen species

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Extracellular matrix metabolism in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Accumulation of worn-out GBM material substantially contributes to mesangial matrix expansion in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

High ambient glucose levels modulates the production of MMP-9 and alpha5(IV) collagen by cultured podocytes

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Podocyte loss and progressive glomerular injury in type II diabetes

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Impact of high glucose and transforming growth factor-β on bioenergetic profiles in podocytes.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Alterations in the expression of the alpha 3 beta 1 integrin in certain membrane domains of the glomerular epithelial cells (podocytes) in diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Apoptosis in podocytes induced by TGF-beta and Smad7

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Nephrin Preserves Podocyte Viability and Glomerular Structure and Function in Adult Kidneys

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

PKC alpha mediates beta-arrestin2-dependent nephrin endocytosis in hyperglycemia

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Podocytic PKC-alpha is regulated in murine and human diabetes and mediates nephrin endocytosis

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

CIN85 Deficiency Prevents Nephrin Endocytosis and Proteinuria in Diabetes

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Defective podocyte insulin signalling through p85-XBP1 promotes ATF6-dependent maladaptive ER-stress response in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Signal integration at the PI3K-p85-XBP1 hub endows coagulation protease activated protein C with insulin-like function.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Insulin signaling to the glomerular podocyte is critical for normal kidney function

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Podocyte mitosis - a catastrophe.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Urinary monocyte chemoattractant protein-1 and hepcidin and early diabetic nephropathy lesions in type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Innate immunity in diabetes and diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Of Inflammasomes and Alarmins: IL-1β and IL-1α in Kidney Disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Targeting inflammation in diabetic kidney disease: early clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production?

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Pattern recognition receptors and the inflammasome in kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Roles of the NLRP3 inflammasome in the pathogenesis of diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Caspase-1, but Not Caspase-3, Promotes Diabetic Nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Epigenetic mechanisms in diabetic complications and metabolic memory

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Gene-nutrient interactions in one-carbon metabolism

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Impact of diets and nutrients/drugs on early epigenetic programming

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

mTORC1 maintains renal tubular homeostasis and is essential in response to ischemic stress

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Role of mTOR in podocyte function and diabetic nephropathy in humans and mice

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Targeting mTOR Signaling Can Prevent the Progression of FSGS.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Reproductive health and pregnancy in women with chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Epidemiology of urinary tract infections in type 2 diabetes mellitus patients: An analysis based on a large sample of 456,586 German T2DM patients

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Kidney biopsy in patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Evaluation of renal biopsies in type 2 diabetic patients with kidney disease: a clinicopathological study of 216 cases.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Cystatin C- and creatinine-based estimated glomerular filtration rate, vascular disease, and mortality in persons with diabetes in the U.S.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

A molecular morphometric approach to diabetic kidney disease can link structure to function and outcome.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Single-Nephron Glomerular Filtration Rate in Healthy Adults

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Glomerular hyperfiltration: definitions, mechanisms and clinical implications.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

What makes cells grow larger and how do they do it? Renal hypertrophy revisited

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Diabetes mellitus as a cause or comorbidity of chronic kidney disease and its outcomes: the Gonryo study

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Renal outcomes in patients with type 2 diabetes with or without coexisting non-diabetic renal disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

The diabetes pandemic suggests unmet needs for 'CKD with diabetes' in addition to 'diabetic nephropathy'-implications for pre-clinical research and drug testing

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

The establishment and validation of novel therapeutic targets to retard progression of chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Hurdles to the introduction of new therapies for immune-mediated kidney diseases

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Risk Factors for Severe Bleeding Complications in Percutaneous Renal Biopsy

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Kidney disease and obesity: epidemiology, mechanisms and treatment.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Mouse models of diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Prevalence of non-diabetic renal disease among African-American patients with type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Prevalence of nondiabetic renal disease in diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Different patterns of renal damage in type 2 diabetes mellitus: a multicentric study on 393 biopsies.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Clinical versus histological diagnosis of diabetic nephropathy--is renal biopsy required in type 2 diabetic patients with renal disease?

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Causes of albuminuria in patients with type 2 diabetes without diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Retinopathy, hematuria, and diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Is there a need for changes in renal biopsy criteria in proteinuria in type 2 diabetes?

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

The Czech registry of renal biopsies. Occurrence of renal diseases in the years 1994-2000.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Renal biopsy in patients with type 2 diabetes mellitus: indications and nature of the lesions

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Non diabetic renal disease in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Rapidly progressive renal failure in type 2 diabetes in the tropical environment: a clinico-pathological study

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Non-diabetic renal disease in patients with type-2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Clinical predictors of non-diabetic renal disease and role of renal biopsy in diabetic patients with renal involvement: a single centre review.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Clinicopathological characteristics of non-diabetic renal disease in patients with type 2 diabetes mellitus in a northeastern Chinese medical center: a retrospective analysis of 273 cases

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Nondiabetic renal disease in type 2 diabetic patients: a review of our experience in 220 cases

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Renal biopsy in type 2 diabetes: timing of complications and evaluating of safety in Chinese patients

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Prevalence of non-diabetic renal disease in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Renal outcome in type 2 diabetic patients with or without coexisting nondiabetic nephropathies

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Renal pathological change in patients with type 2 diabetes is not always diabetic nephropathy: a report of 52 cases

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Clinical predictors of non-diabetic renal disease in patients with non-insulin dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Clinical indicators which necessitate renal biopsy in type 2 diabetes mellitus patients with renal disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Significance of renal biopsy in patients with presumed diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Nondiabetic renal disease complicating diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Clinical features of non-diabetic renal diseases in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Microscopic hematuria and diabetic glomerulosclerosis--clinicopathological analysis of type 2 diabetic patients associated with overt proteinuria

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

Non-diabetic renal disease in patients with non-insulin dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0001-Y

7 January 2021

10.1038/S41581-018-0001-Y

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29654297%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

1 reference